Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | ACACB | O00763 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.44 |
| ▸ | ME3 | Q16798 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21625630 | 1.00 | NOTUM (0.55) | NOTUMSIGMAR1MCHR1ACACBTRPV1 | |
| SCHEMBL21624686 | 0.90 | NOTUM (0.53) | NOTUMSIGMAR1ACACBTRPV1ME3 | |
| SCHEMBL21624688 | 0.90 | NOTUM (0.53) | NOTUMSIGMAR1ACACBTRPV1ME3 | |
| SCHEMBL12894863 | 0.83 | SIGMAR1 (0.67) | NOTUMSIGMAR1ME3 | |
| SCHEMBL23387378 | 0.82 | NOTUM (0.68) | NOTUMACACB | |
| SCHEMBL23387375 | 0.82 | NOTUM (0.68) | NOTUMACACB | |
| SCHEMBL21624787 | 0.82 | NOTUM (0.48) | NOTUMSIGMAR1ACACBTRPV1AOC3 | |
| SCHEMBL21624626 | 0.80 | CCNC (0.55) | NOTUMSIGMAR1TRPV1TEAD1ME3 | |
| SCHEMBL21624627 | 0.80 | CCNC (0.55) | NOTUMSIGMAR1TRPV1TEAD1ME3 | |
| SCHEMBL21624755 | 0.80 | SIGMAR1 (0.53) | NOTUMSIGMAR1MCHR1TEAD1ME3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | claimed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | claimed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | claimed |
| WO-2020203609-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | claimed |
| WO-2020203610-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | claimed |
| WO-2020017569-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日本ケミファ株式会社 | 2020-01-23 | — | — | WO | claimed |
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-11-17 | — | — | US | disclosed |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | NIPPON CHEMIPHAR CO., LTD. (JP) | 2022-07-21 | — | — | US | disclosed |
| EP-3950059-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | Nippon Chemiphar Co., Ltd. (JP) | 2022-02-09 | — | — | EP | disclosed |
| EP-3825303-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nippon Chemiphar Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| WO-2020203609-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020203610-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING RHEUMATOID ARTHRITIS | 日本ケミファ株式会社 | 2020-10-08 | — | — | WO | disclosed |
| WO-2020017569-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日本ケミファ株式会社 | 2020-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220363667-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | CACNA1I, CACNA1G, CACNA1H | NOTUM 3172/4885SIGMAR1 732/4885MCHR1 2447/4885 |
| US-20220226299-A1 | USE OF T-TYPE CALCIUM CHANNEL BLOCKER FOR TREATING PRURITUS | TRPV3, CACNA1G, TRPV2 | NOTUM 1650/4885SIGMAR1 1981/4885MCHR1 2380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.